Previous 10 | Next 10 |
NEW YORK , Sept. 15, 2020 /PRNewswire/ -- Moore Kuehn, PLLC, a securities litigation law firm located on Wall Street in downtown New York City , is investigating potential claims concerning whether the following proposed mergers are fair to shareholders. Moore Kuehn may ultima...
NEW YORK , Sept. 15, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, is investigating: Rosetta Stone Inc. (NYSE: RST) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its...
Mergers have been lagging Mergers for 2020 have vastly lagged last year. This has been a cause of concern for me in judging the health of the stock market. For the raison d'etres of Wall Street is not to make us rich, it's to create a source of equity capital to build companies. Our role...
Japanese High In 1989, the Japanese Nikkei hit 38,916. It was a time of craziness. The Emperor's palace was valued at equal to all of the real estate in California. Such prices are unsustainable. The Nikkei 30 years out sits at 23,205. Someday, the high point of the Nikkei will be surpassed,...
On Sunday and Monday, September 13th and 14th, two of the largest ever deals for ADC (antibody-drug conjugate) drugs were struck. In a span less than 24 hours, it was announced that Gilead ( GILD ) would pay $21B to purchase Immunomedics (IMMU) for their TROP-2 targeting ADC, Trodelvy, and tha...
Many investors have long hoped that Gilead Sciences (NASDAQ: GILD) would use its massive cash stockpile to fund a major acquisition. That hope is now being fulfilled. Gilead announced on Sunday that it plans to acquire Immunomedics (NASDAQ: IMMU) for around $21 billion. At nearly...
Merger activity decreased last week, with two new deals announced, but one of these was a blockbuster deal worth $21 billion and at a 108% premium to Friday's closing price. None of the pending active deals were completed last week. There was also a private deal nearly double the size of the...
Top Biotech Stocks To Buy [Or Sell] In September 2020 Biotech stocks have been among the typical investments for investors looking for strong growth prospects. The biotech industry is part of the broader healthcare sector . Not only does it create opportunities for long-term investors , bu...
Article Thesis Gilead Sciences ( GILD ) has a history of large takeovers, some of them more successful than others. The company has now decided to acquired Immunomedics ( IMMU ) for $21 billion. At first sight, this deal seems quite expensive, but maybe investors should put some trust in the...
Gilead Sciences (GILD) has hit the news cycles with reports of a $21 billion deal to buy Immunomedics (IMMU). The massive deal involves $15 billion of cash on hand and $6 billion in new debt. The company already spent $3.1 billion net this year on its Forty Seven acquisition. We expect the m...
News, Short Squeeze, Breakout and More Instantly...
Gilead Sciences (NASDAQ: GILD) can be both a hero and a goat, depending on your perspective as an investor. The stock price rose from $17 in July 2010 to $118 in July 2015, as the company introduced revolutionary HIV drugs and helped bring a cure for hepatitis C to market. Since the...
With huge investments being made in biotech thanks to the pandemic, there has been a renewed focus on biotech stocks. Here are three worth considering: Amgen (AMGN), Immunomedics (IMMU), Seattle Genetics (SGEN), and Genmab (GMAB). The biotechnology industry has rightfully received a huge ...
MORRIS PLAINS, N.J., Oct. 12, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced that the Office of Orphan Products...